Gleason Group’s AstraZeneca AZN Stock Holding History

Gleason Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.46K	Hold	40	–	–	﹤0.01%	265
2026 Q2	$7.58K	Buy	+40	New	+$7.52K	﹤0.01%	255

Other funds holding AZN

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $28B AUM 17.3% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $103B AUM 36.66% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Gleason Group's AZN Position: Q3 2026 in Review

Gleason Group held its AstraZeneca (AZN) position steady in Q3 2026 at 40 shares worth $6.46K. The position accounts for ﹤0.01% of the portfolio, ranked #265.

Gleason Group first reported a position in AZN in Q2 2026 and has held it in 2 quarters since. The position peaked at $7.58K in Q2 2026. 934 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

Gleason Group held 40 shares of AstraZeneca worth $6.46K as of Q3 2026.
Gleason Group left its AstraZeneca share count unchanged in Q3 2026.
AstraZeneca made up ﹤0.01% of Gleason Group's portfolio in Q3 2026, its #265 holding.
Gleason Group first reported a position in AstraZeneca in Q2 2026 and has held it in 2 quarters since.
Gleason Group's AstraZeneca position peaked at $7.58K in Q2 2026.
934 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Gleason Group's 13F filing for Q3 2026, filed 15 Oct 2026.